A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function

다국어 초록 (Multilingual Abstract)

Purpose Finasteride, a 5α-reductase inhibitor, is used in clinical practice to treat benign prostatic hyperplasia and androgenetic alopecia. However, scientific and quantitative dosage regimen studies for finasteride are lacking. This study explored effective finasteride covariates related to inter-individual pharmacokinetic (PK) variability through population PK modeling and their quantitative correlations.
Methods We used bioequivalence PK results from healthy Korean males for modeling. We considered the physiological and biochemical parameters obtained from each individual and CYP3A5 genotyping information in the covariate search process.
We investigated the genetic polymorphisms of CYP3A5 and alanine transaminase (ALT) as effective covariates for clearance (CL/F) in inter-individual finasteride PK variability.
Results The homozygous (*3/*3) CYP3A5*3 allele had approximately 34% lower CL/F than the *1 allele carriers (*1/*1 and *1/*3), and the CL/F decreased as ALT increased. The established model explained the data sets of multiple-dose groups and subjects derived from external sources. The model simulation revealed that the mean finasteride plasma or serum concentration at steady state was significantly increased by approximately 1.59–1.83 fold with the *3/*3 genotype of CYP3A5, and the ALT level was higher than 40 IU/L.
Conclusion This suggests that the CYP3A5 genotype is *3 allele homozygous or that, with increased hepatic impairment, continued exposure to high doses of finasteride can lead to adverse side effects. It was quantitatively confirmed that the dosage might have to be adjusted, considering the CYP3A5 and ALT genotypes. Thus, this study will aid in the clinical application of finasteride.

참고문헌 (Reference)

1 이용복 ; 강현아 ; 조혜영, "프로스카 정(피나스테리드 5 mg)에 대한 푸로케어 정의 생물학적동등성" 한국약제학회 36 (36): 143-148, 2006

2 Launer BM, "The rising worldwide impact of Benign Prostatic Hyperplasia" 127 (127): 722-728, 2021

3 Liu BY, "The effects of CYP3A5 genetic polymorphisms on serum Tacrolimus dose-adjusted concentrations and long-term prognosis in Chinese Heart Transplantation recipients" 44 (44): 771-776, 2019

4 Lundahl A, "The effect of St. John’s wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men" 36 (36): 433-443, 2009

5 Loughlin KR, "The clinical applications of five-alpha reductase inhibitors" 28 (28): 10584-10588, 2021

6 Phapale PB, "Rapid determination of finasteride in human plasma by UPLC–MS/MS and its application to clinical pharmacokinetic study" 878 (878): 1718-1723, 2010

7 Pourshams A, "Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors" 20 (20): 229-233, 2005

8 Diviccaro S, "Post-finasteride syndrome : an emerging clinical problem" 12 : 100209-, 2019

9 Jang JH, "Population pharmacokinetics of Cis, Trans, and total cefprozil in healthy male koreans" 11 (11): 531-545, 2019

10 정승현 ; 장지훈 ; 이용복, "Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism" 한국약제학회 52 (52): 109-127, 2022

11 Jeong SH, "Population Pharmacokinetic Analysis of Tiropramide in healthy Korean subjects" 12 (12): 374-393, 2020

12 Jeong SH, "Population Pharmacokinetic Analysis of Cefaclor in healthy Korean subjects" 13 (13): 754-, 2021

13 Ohtawa M, "Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers" 16 (16): 15-21, 1991

14 Vannaprasaht S, "Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation" 35 (35): 1762-1769, 2013

15 FDA, "PROSCAR® (finasteride) Tablets"

16 Huskey S, "Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride" 23 (23): 1126-1135, 1995

17 Mysore V, "Guidelines on the use of finasteride in androgenetic alopecia" 82 (82): 128-134, 2016

18 Peters DH, "Finasteride. A review of its potential in the treatment of Benign Prostatic Hyperplasia" 46 (46): 177-208, 1993

19 Leyden J, "Finasteride in the treatment of men with frontal male pattern hair loss" 40 (40): 930-937, 1999

20 Chau CH, "Finasteride concentrations and Prostate cancer risk : results from the Prostate Cancer Prevention Trial" 10 (10): e0126672-, 2015

21 Lokeshwar SD, "Epidemiology and treatment modalities for the management of Benign Prostatic Hyperplasia" 8 (8): 529-539, 2019

22 Ptáček P, "Determination of finasteride in human plasma by liquid–liquid extraction and high-performance liquid chromatography" 738 (738): 305-310, 2000

23 Yuan L, "Determination of finasteride in human plasma by liquid chromatography–electrospray ionization tandem mass spectrometry with flow rate gradient" 35 (35): 137-146, 2011

24 Steiner JF, "Clinical pharmacokinetics and pharmacodynamics of finasteride" 30 (30): 16-27, 1996

25 Cilotti A, "Clinical application of 5α-reductase inhibitors" 24 (24): 199-203, 2001

26 Haufroid V, "CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates : guidelines from an experimental study" 6 (6): 2706-2713, 2006

27 Almeida A, "Bioequivalence study of two different coated tablet formulations of finasteride in healthy volunteers" 55 (55): 218-222, 2005

28 Khangtragool A, "Bioequivalence study of generic finasteride in healthy male volunteers" 42 (42): 131-137, 2003

29 Chen L, "Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers : a randomized sequence, open-label, two-way crossover study" 31 (31): 2242-2248, 2009

30 Guo FQ, "A rapid, simple, specific liquid chromatographic–electrospray mass spectrometry method for the determination of finasteride in human plasma and its application to pharmacokinetic study" 43 (43): 1507-1513, 2007

31 Mousavi SHH, "A rapid, simple, liquid chromatographic-electrospray ionization, ion trap mass spectrometry method for the determination of finasteride in human plasma and its application to pharmacokinetic study" 11 (11): 59-67, 2012

32 Gisleskog PO, "A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride" 64 (64): 636-647, 1998